Recombinant human interferon α1b (rhIFN-α1b), as China's first independently developed class I new drug of genetic engineering, has unique biological characteristics in its molecular structure. This protein consists of 165 amino acids with a molecular weight of 19.3 kDa, and its spatial structure presents a typical α-helical bundle fold. Compared with the IFN-α2 subtype derived from Western populations, rhIFN-α1b has significant differences in amino acids at positions 23 and 34. This structural feature reduces the binding free energy with the IFNAR2 receptor by 2.3 kcal/mol, optimizes the dissociation constant (Kd) by approximately 1.8 times, and exhibits stronger receptor affinity (1.2×10⁻¹⁰ M).
In terms of the mechanism of action, rhIFN-α1b exerts antiviral effects through dual pathways: on the one hand, it activates the classical JAK-STAT signaling pathway to induce the expression of various antiviral proteins such as 2'-5' oligoadenylate synthetase (OAS1/2), myxovirus resistance protein A (MxA), and protein kinase R (PKR); on the other hand, it upregulates the expression of major histocompatibility complex (MHC) class I/II molecules, promotes the activation of CD8⁺ T cells (in vitro experiments show that the proliferation index can be increased by 3-5 times), and enhances the activity of natural killer (NK) cells (the killing rate reaches 85% when the effector-target ratio is 1:20). It is worth noting that rhIFN-α1b has a significantly better inhibitory effect on common respiratory viruses in China, such as respiratory syncytial virus (RSV) and parainfluenza virus (PIV), than imported α2 subtype interferons, and this characteristic is closely related to its unique receptor binding features.
Pharmacokinetic studies of rhIFN-α1b in pediatric applications show significant differences in different administration routes. After nebulization inhalation, the concentration of the drug in the respiratory mucosa can reach 5-8 times that in plasma, and the half-life is extended to 8-12 hours; while the bioavailability of intramuscular injection is over 85%, and the time to peak concentration is 4-8 hours. Studies in special populations indicate that the drug clearance rate in premature infants (corrected gestational age ≥34 weeks) is about 30% lower than that in full-term infants, but no dose adjustment is needed; the area under the plasma concentration-time curve (AUC) in children with mild abnormal liver function may increase by 15-20%, and enhanced monitoring is recommended.
A comprehensive analysis of safety data shows that the overall incidence of adverse reactions with nebulization inhalation (3.0‰) is significantly lower than that with intramuscular injection (17.3‰). Specifically, the incidence of fever is 2.1‰ and 12.3‰ respectively, and leukopenia is 0.3‰ and 5.8‰ respectively. A long-term follow-up study (n=1,205) confirmed that rhIFN-α1b has no significant impact on children's growth and development (height Z-score difference -0.12±0.35), and the incidence of abnormal thyroid function is not statistically different from that of the control group (2.3% vs 1.8%).
Based on the latest evidence from 23 multi-center randomized controlled trials, rhIFN-α1b has shown significant efficacy in six categories of pediatric viral diseases:
Respiratory Viral Infections
In the treatment of bronchiolitis, starting nebulization therapy within 72 hours of onset (4μg/kg, twice daily) can shorten the duration of wheezing to 3.2±0.8 days (control group 5.1±1.2 days, P<0.01), and the viral load in RSV-positive children decreases by 2.5 log levels on day 5. For severe pneumonia, a stepwise regimen is recommended: mild cases receive nebulization of 2μg/kg twice daily for 5 days, and severe cases receive nebulization of 4μg/kg twice daily combined with intramuscular injection of 1μg/kg once daily for 7 days.
Enteroviral Infections
For severe hand, foot, and mouth disease with neurological symptoms caused by EV71 infection, the intensive treatment regimen (nebulization of 4μg/kg combined with intramuscular injection of 2μg/kg) can reduce the incidence of brainstem encephalitis by 42% (8.3% vs 14.2%) and shorten the average hospital stay by 2.3 days. In the treatment of herpetic angina, rhIFN-α1b can significantly promote the healing of oral herpes (healing time shortened by 1.8 days) and show obvious analgesic effect.
Chronic Viral Hepatitis
The most significant adjustment in the treatment regimen is for children with chronic hepatitis B. Based on 10-year follow-up data (n=1,205), extending the course of treatment to 48 weeks can increase the HBeAg seroconversion rate to 58.3% (42.1% in the 24-week group). It is worth noting that the growth and development indicators of children in the rhIFN-α1b treatment group are not significantly different from those in the normal control group.
The new chapter of this consensus provides specific recommendations for drug use in special populations:
Immunocompromised children: It is recommended to reduce the dose by 25%.
Critically ill children in intensive care: The administration interval should be adjusted to once every 8 hours.
Children with congenital heart disease: Cardiac ultrasound evaluation is required before and after treatment.
It also emphasizes the importance of individualized treatment, and it is recommended to carry out the following when conditions permit:
Pharmacogenomic testing (such as OAS3 rs1859330 polymorphism analysis)
Therapeutic drug monitoring (target trough concentration >50 IU/mL)
Development of new drug delivery systems: Long-acting microsphere preparations can maintain effective concentration for 72 hours.
Expansion of indication range: Explore the potential role in SARS-CoV-2 infection.
Establishment of precise medication system: Individualized treatment 方案 based on biomarkers.
It should be particularly noted that high-quality research on infants under 2 months of age is still insufficient. Limited data show that under close monitoring, a dose of 1μg/kg may be safe and effective for neonatal viral pneumonia, but more evidence-based medical evidence is still needed.
The following key points should be noted in clinical use:
Strictly grasp the indication
Choose the best administration route according to the condition
Standardize the monitoring process of adverse reactions
Establish treatment files to record baseline indicators and follow-up data
Business license (three certificates in one) 